ClinVar Miner

Submissions for variant NM_032043.2(BRIP1):c.1165G>T (p.Val389Phe) (rs587780825)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000485017 SCV000570306 uncertain significance not provided 2016-05-13 criteria provided, single submitter clinical testing This variant is denoted BRIP1 c.1165G>T at the cDNA level, p.Val389Phe (V389F) at the protein level, and results in the change of a Valine to a Phenylalanine (GTT>TTT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRIP1 Val389Phe was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Valine and Phenylalanine differ in some properties, this is considered a semi-conservative amino acid substitution. BRIP1 Val389Phe occurs at a position where amino acids with properties similar to Valine are tolerated across species and is located within the helicase and helicase ATP-binding domain (Cantor 2011, Uniprot). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether BRIP1 Val389Phe is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.